Valuation : Bolt Biotherapeutics, Inc.

Market Cap 7.44M 6.39M 6.02M 5.49M 10.26M 707M 10.31M 71.25M 27.54M 361M 27.91M 27.31M 1.14B P/E 2026 *
-0.16x
P/E 2027 * -0.18x
Enterprise Value 7.44M 6.39M 6.02M 5.49M 10.26M 707M 10.31M 71.25M 27.54M 361M 27.91M 27.31M 1.14B EV / Sales 2026 *
37.2x
EV / Sales 2027 * 2.12x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day-4.71%
1 week-9.63%
Current month-7.59%
1 month-9.18%
3 months-22.07%
6 months-14.46%
Current year-32.73%
1 week 3.53
Extreme 3.53
4
1 month 3.13
Extreme 3.13
4.27
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
352.4
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 15/05/2024
Chief Executive Officer 55 15/05/2024
Chief Operating Officer 61 15/05/2024
Director TitleAgeSince
Director/Board Member 64 01/12/2020
Director/Board Member 55 15/05/2024
Chairman 56 04/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
6/10/26 A Free

Chairman

5,000 0.2602%
1/28/26 A Free

Chief Operating Officer

10,000 0.5210%
1/28/26 A Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
-4.71%-9.63%-28.58%-83.43% 7.44M
-0.94%+0.31%+40.04%+103.25% 69.19B
-0.07%-2.37%+33.44%+78.50% 62.97B
+3.13%+6.00%-12.19%+390.48% 27.27B
-0.54%-3.74%-4.41%-18.31% 24.78B
-0.93%-1.29%+25.30%+16.70% 25.8B
-1.43%-0.61%+22.71%-19.01% 20.11B
-4.27%+2.67%+219.02%+362.48% 18.47B
-1.43%-1.80%-8.64%+537.09% 14.88B
+1.14%+2.53%+54.76%+163.82% 14.29B
Average -0.90%-0.79%+34.14%+153.16% 27.78B
Weighted average by Cap. -0.39%-0.76%+36.87%+141.69%

Financials

2026 *2027 *
Net sales 200K 172K 162K 148K 276K 19.03M 277K 1.92M 741K 9.7M 751K 735K 30.71M 3.5M 3.01M 2.83M 2.58M 4.83M 333M 4.85M 33.54M 12.96M 170M 13.14M 12.85M 537M
Net income -47.4M -40.74M -38.35M -34.99M -65.4M -4.51B -65.69M -454M -176M -2.3B -178M -174M -7.28B -47.5M -40.83M -38.43M -35.07M -65.54M -4.52B -65.83M -455M -176M -2.3B -178M -174M -7.29B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
09/09/26 $3.678 -4.71% 4,258
08/09/26 $3.860 -1.03% 7,348
04/09/26 $3.900 +0.13% 8,506
03/09/26 $3.895 +1.43% 5,553
02/09/26 $3.840 -5.65% 34,539
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.678USD
Average target price
29.00USD
Spread / Average Target
+688.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!